InformAI wins FDA clearance for AI radiation planning software

InformAI has received 510(k) clearance from the FDA to market RadOncAI, an AI-enabled software tool for radiation therapy dose planning in head and neck cancer. The clearance lets InformAI sell the product in the U.S. and marks a key regulatory step for the company’s healthcare AI portfolio.

Why it matters: - RadOncAI is designed to help radiation oncologists generate dose plans more efficiently while reducing exposure to nearby healthy tissue. - FDA clearance opens the door for InformAI to market and distribute the software in the United States. - The product targets head and neck cancer, where precision in dose planning can affect both treatment quality and side effects.

What happened: - InformAI received 510(k) clearance from the U.S. Food and Drug Administration for RadOncAI. - The company said the software is an AI-enabled clinician co-pilot and software-as-a-medical-device for radiation therapy dose planning. - InformAI announced the clearance on July 15, 2026, in Houston.

The details: - RadOncAI generates an optimized radiation dose plan intended to target tumors while minimizing radiation to adjacent healthy tissue. - The product is built for the key planning step in radiation therapy for head and neck cancer patients. - InformAI said the development included clinical research testing on a patient cohort of more than 900 patients. - The clearance indicates the product met FDA safety and efficacy standards for its intended use. - The software includes InformAI proprietary IP and licensed IP from the University of Texas Southwestern Medical Center. - InformAI also cited support from the Cancer Prevention and Research Initiative of Texas for grant DP220063, which helped fund product development. - CEO and Founder Jim Havelka said the clearance is a major step in the company’s mission and believes RadOncAI will help radiation oncologists create quality dose plans more efficiently.

Between the lines: - The clearance gives InformAI a regulatory foothold in a specialized oncology workflow, which could help the company position its AI tools as clinically usable rather than experimental. - The use of both proprietary and licensed academic IP suggests the product combines internal development with outside research expertise. - The 900-patient research base may help support clinician confidence and future adoption, though real-world uptake will still depend on workflow fit and hospital buying decisions.

What's next: - InformAI can now sell RadOncAI in the U.S. market. - The company is likely to use the clearance to expand its AI healthcare portfolio and pursue broader adoption in oncology settings. - Further commercial rollout will depend on how radiation oncology teams integrate the software into existing planning systems.

The bottom line: - RadOncAI’s FDA clearance turns InformAI’s radiation planning tool into a marketable medical product and gives the company a clearer path into clinical oncology workflows.